We observed that treatment with Ro5‐3335 effectively blocked LLC tumor progression (Figure7A,B) via inhibiting CAF formation (α‐SMA and FAP) in vivo (Figure 7C), without any observed adverse effects (Figure S6, Supporting Information). Here, ACTA1 is linked to neoplasm.